| The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Rethinking clinical trial endpoints in myelodysplastic syndromes. |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia. |
|
Haematologica |
Aplastic Anemia |
| Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. |
|
Cancer Med |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. |
|
Biol Blood Marrow Transplant. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
|
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
| Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal Hematopoiesis and therapy related MDS/AML |
|
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
|
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
| A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
